Literature DB >> 32249318

Altered Signaling in CB1R-5-HT2AR Heteromers in Olfactory Neuroepithelium Cells of Schizophrenia Patients is Modulated by Cannabis Use.

Daniel Guinart1,2,3, Estefanía Moreno4,5, Liliana Galindo1,6, Aida Cuenca-Royo7, Marta Barrera-Conde7,8, Ezequiel J Pérez1, Cristina Fernández-Avilés1, Christoph U Correll3,9, Enric I Canela4,5, Vicent Casadó4,5, Arnau Cordomi10, Leonardo Pardo10, Rafael de la Torre7,11, Víctor Pérez1,2,12, Patricia Robledo7,8.   

Abstract

Schizophrenia (SCZ) has been associated with serotonergic and endocannabinoid systems dysregulation, but difficulty in obtaining in vivo neurological tissue has limited its exploration. We investigated CB1R-5-HT2AR heteromer expression and functionality via intracellular pERK and cAMP quantification in olfactory neuroepithelium (ON) cells of SCZ patients non-cannabis users (SCZ/nc), and evaluated whether cannabis modulated these parameters in patients using cannabis (SCZ/c). Results were compared vs healthy controls non-cannabis users (HC/nc) and healthy controls cannabis users (HC/c). Further, antipsychotic effects on heteromer signaling were tested in vitro in HC/nc and HC/c. Results indicated that heteromer expression was enhanced in both SCZ groups vs HC/nc. Additionally, pooling all 4 groups together, heteromer expression correlated with worse attentional performance and more neurological soft signs (NSS), indicating that these changes may be useful markers for neurocognitive impairment. Remarkably, the previously reported signaling properties of CB1R-5-HT2AR heteromers in ON cells were absent, specifically in SCZ/nc treated with clozapine. These findings were mimicked in cells from HC/nc exposed to clozapine, suggesting a major role of this antipsychotic in altering the quaternary structure of the CB1R-5-HT2AR heteromer in SCZ/nc patients. In contrast, cells from SCZ/c showed enhanced heteromer functionality similar to HC/c. Our data highlight a molecular marker of the interaction between antipsychotic medication and cannabis use in SCZ with relevance for future studies evaluating its association with specific neuropsychiatric alterations.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  antipsychotics; cannabis; cognition; human olfactory neuroepithelium; schizophrenia

Year:  2020        PMID: 32249318      PMCID: PMC7846100          DOI: 10.1093/schbul/sbaa038

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  59 in total

1.  Cannabis Users Show Enhanced Expression of CB1-5HT2A Receptor Heteromers in Olfactory Neuroepithelium Cells.

Authors:  Liliana Galindo; Estefanía Moreno; Fernando López-Armenta; Daniel Guinart; Aida Cuenca-Royo; Mercè Izquierdo-Serra; Laura Xicota; Cristina Fernandez; Esther Menoyo; José M Fernández-Fernández; Gloria Benítez-King; Enric I Canela; Vicent Casadó; Víctor Pérez; Rafael de la Torre; Patricia Robledo
Journal:  Mol Neurobiol       Date:  2018-01-02       Impact factor: 5.590

2.  Polygenic risk for schizophrenia and associated brain structural changes: A systematic review.

Authors:  C van der Merwe; R Passchier; M Mufford; R Ramesar; S Dalvie; D J Stein
Journal:  Compr Psychiatry       Date:  2018-11-29       Impact factor: 3.735

Review 3.  Mitogen-activated protein kinases in synaptic plasticity and memory.

Authors:  J David Sweatt
Journal:  Curr Opin Neurobiol       Date:  2004-06       Impact factor: 6.627

Review 4.  Neuronal and brain morphological changes in animal models of schizophrenia.

Authors:  Gonzalo Flores; Julio César Morales-Medina; Alfonso Diaz
Journal:  Behav Brain Res       Date:  2015-12-29       Impact factor: 3.332

5.  Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia.

Authors:  Kimberly J Jenko; Jussi Hirvonen; Ioline D Henter; Kacey B Anderson; Sami S Zoghbi; Thomas M Hyde; Amy Deep-Soboslay; Robert B Innis; Joel E Kleinman
Journal:  Schizophr Res       Date:  2012-08-19       Impact factor: 4.939

Review 6.  The longitudinal course of cognitive impairment in schizophrenia: an examination of data from premorbid through posttreatment phases of illness.

Authors:  Richard S E Keefe
Journal:  J Clin Psychiatry       Date:  2014       Impact factor: 4.384

Review 7.  The microtubular cytoskeleton of olfactory neurons derived from patients with schizophrenia or with bipolar disorder: Implications for biomarker characterization, neuronal physiology and pharmacological screening.

Authors:  G Benítez-King; M Valdés-Tovar; C Trueta; T Galván-Arrieta; J Argueta; S Alarcón; A Lora-Castellanos; H Solís-Chagoyán
Journal:  Mol Cell Neurosci       Date:  2016-02-04       Impact factor: 4.314

Review 8.  Epigenetic mechanisms in schizophrenia.

Authors:  Tania L Roth; Farah D Lubin; Monsheel Sodhi; Joel E Kleinman
Journal:  Biochim Biophys Acta       Date:  2009-06-25

9.  Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort.

Authors:  Anja P Husa; Jani Moilanen; Graham K Murray; Riikka Marttila; Marianne Haapea; Irina Rannikko; Jennifer H Barnett; Peter B Jones; Matti Isohanni; Anne M Remes; Hannu Koponen; Jouko Miettunen; Erika Jääskeläinen
Journal:  Psychiatry Res       Date:  2016-11-12       Impact factor: 3.222

10.  Chronic cannabis promotes pro-hallucinogenic signaling of 5-HT2A receptors through Akt/mTOR pathway.

Authors:  Inés Ibarra-Lecue; Irene Mollinedo-Gajate; J Javier Meana; Luis F Callado; Rebeca Diez-Alarcia; Leyre Urigüen
Journal:  Neuropsychopharmacology       Date:  2018-04-27       Impact factor: 7.853

View more
  4 in total

Review 1.  G protein-coupled receptor-effector macromolecular membrane assemblies (GEMMAs).

Authors:  Sergi Ferré; Francisco Ciruela; Carmen W Dessauer; Javier González-Maeso; Terence E Hébert; Ralf Jockers; Diomedes E Logothetis; Leonardo Pardo
Journal:  Pharmacol Ther       Date:  2021-09-01       Impact factor: 13.400

Review 2.  Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders.

Authors:  Daniela Navarro; Ani Gasparyan; Francisco Navarrete; Abraham B Torregrosa; Gabriel Rubio; Marta Marín-Mayor; Gabriela B Acosta; Maria Salud Garcia-Gutiérrez; Jorge Manzanares
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

3.  Cannabis Use Induces Distinctive Proteomic Alterations in Olfactory Neuroepithelial Cells of Schizophrenia Patients.

Authors:  Marta Barrera-Conde; Karina Ausin; Mercedes Lachén-Montes; Joaquín Fernández-Irigoyen; Liliana Galindo; Aida Cuenca-Royo; Cristina Fernández-Avilés; Víctor Pérez; Rafael de la Torre; Enrique Santamaría; Patricia Robledo
Journal:  J Pers Med       Date:  2021-02-25

Review 4.  Endocannabinoid-mediated neuromodulation in the main olfactory bulb at the interface of environmental stimuli and central neural processing.

Authors:  Thomas Heinbockel; Naina Bhatia-Dey; Vonnie D C Shields
Journal:  Eur J Neurosci       Date:  2021-04-02       Impact factor: 3.698

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.